<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">        <PMID Version="1">30046669</PMID>        <DateRevised>            <Year>2018</Year>            <Month>07</Month>            <Day>29</Day>        </DateRevised>        <Article PubModel="Electronic-eCollection">            <Journal>                <ISSN IssnType="Electronic">2475-0379</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>1</Volume>                    <Issue>1</Issue>                    <PubDate>                        <Year>2017</Year>                        <Month>Jul</Month>                    </PubDate>                </JournalIssue>                <Title>Research and practice in thrombosis and haemostasis</Title>                <ISOAbbreviation>Res Pract Thromb Haemost</ISOAbbreviation>            </Journal>            <ArticleTitle>Occult cancer detection in venous thromboembolism: the past, the present, and the future.</ArticleTitle>            <Pagination>                <MedlinePgn>9-13</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1002/rth2.12007</ELocationID>            <Abstract>                <AbstractText/>                <AbstractText>Unprovoked venous thromboembolism (VTE) can be the first manifestation of an undiagnosed cancer. Recently published studies have suggested that approximately 4-5% of patients with new unprovoked VTE will be diagnosed with cancer within 12Â months of follow-up. Therefore, it is important for clinicians to keep a low threshold of suspicion for occult cancer in this patient population. After an unprovoked VTE diagnosis, patients should undergo a thorough medical history, physical examination, basic laboratory investigations (ie, complete blood count and liver function tests), chest X-ray, as well as age- and gender-specific cancer screening (breast, cervical, colon, and prostate). More intensive cancer screening including additional investigations (eg, computed tomography of the abdomen/pelvis) does not seem to increase the rate of occult cancer detection, decrease cancer-related morbidity, or increase survival or cost-effectiveness.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Khan</LastName>                    <ForeName>Faizan</ForeName>                    <Initials>F</Initials>                    <AffiliationInfo>                        <Affiliation>School of Epidemiology, Public Health &amp; Preventive Medicine University of Ottawa Ottawa ON Canada.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Clinical Epidemiology Program Ottawa Hospital Research Institute Ottawa ON Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Rahman</LastName>                    <ForeName>Alvi</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>School of Epidemiology, Public Health &amp; Preventive Medicine University of Ottawa Ottawa ON Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Carrier</LastName>                    <ForeName>Marc</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Clinical Epidemiology Program Ottawa Hospital Research Institute Ottawa ON Canada.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Medicine Ottawa Blood Disease Centre University of Ottawa and The Ottawa Hospital Ottawa ON Canada.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D016454">Review</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2017</Year>                <Month>06</Month>                <Day>16</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Res Pract Thromb Haemost</MedlineTA>            <NlmUniqueID>101703775</NlmUniqueID>            <ISSNLinking>2475-0379</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Thromb Res. 2017 Mar;151:67-71</RefSource>                <PMID Version="1">28160670</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Thromb Haemost. 2005 Nov;3(11):2391-6</RefSource>                <PMID Version="1">16241936</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>N Engl J Med. 2015 Dec 17;373(25):2474-5</RefSource>                <PMID Version="1">26672852</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Intern Med. 2008 Sep 2;149(5):323-33</RefSource>                <PMID Version="1">18765702</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Thromb Haemost. 2004 Jun;2(6):884-9</RefSource>                <PMID Version="1">15140122</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet Oncol. 2016 Feb;17(2):193-199</RefSource>                <PMID Version="1">26672686</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Epidemiol Biomarkers Prev. 2014 May;23(5):774-83</RefSource>                <PMID Version="1">24608188</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Thromb Thrombolysis. 2016 Jan;41(1):81-91</RefSource>                <PMID Version="1">26780740</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>JAMA Intern Med. 2016 Jun 1;176(6):739-40</RefSource>                <PMID Version="1">27159419</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Semin Thromb Hemost. 2016 Nov;42(8):884-890</RefSource>                <PMID Version="1">27764880</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMJ. 1994 Apr 2;308(6933):891-4</RefSource>                <PMID Version="1">8173368</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Intern Med. 1996 Nov 15;125(10):785-93</RefSource>                <PMID Version="1">8928984</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Chest. 2017 Mar;151(3):564-571</RefSource>                <PMID Version="1">27815153</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>N Engl J Med. 2015 Aug 20;373(8):697-704</RefSource>                <PMID Version="1">26095467</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Radiol. 2016 Jun;71(6):501-6</RefSource>                <PMID Version="1">27005017</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Blood. 2016 Apr 21;127(16):2035-7</RefSource>                <PMID Version="1">26817957</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Thromb Haemost. 2011 Jan;9(1):79-84</RefSource>                <PMID Version="1">20946181</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Thromb Haemost. 2004 Jun;2(6):876-81</RefSource>                <PMID Version="1">15140120</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">early detection screening</Keyword>            <Keyword MajorTopicYN="N">neoplasm</Keyword>            <Keyword MajorTopicYN="N">tomography</Keyword>            <Keyword MajorTopicYN="N">venous thromboembolism</Keyword>            <Keyword MajorTopicYN="N">venous thrombosis</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>7</Month>                <Day>27</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>7</Month>                <Day>27</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>7</Month>                <Day>27</Day>                <Hour>6</Hour>                <Minute>1</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30046669</ArticleId>            <ArticleId IdType="doi">10.1002/rth2.12007</ArticleId>            <ArticleId IdType="pii">RTH212007</ArticleId>            <ArticleId IdType="pmc">PMC6058204</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>